论文部分内容阅读
美国肝病学会(AASLD)发表的慢性乙型肝炎的治疗指南认为,HBeAg阳性的慢性乙型肝炎患者如果ALT正常,尽管患者确实存在发生肝细胞肝癌(HCC)的危险,但不推荐抗病毒治疗。本文作者针对该治疗指南向“Hepatology”编者提出自己的不同观点,并得到相应回复。现作一报道。 致编者(Geier等):目前,全球慢性HBV感染者达3.5亿,是引起肝硬化和肝癌的主要原因,也是当今人类十大主要死亡原因之一。对慢性HBV感染
Guidelines for the treatment of chronic hepatitis B published by the American College of Hepatology (AASLD) suggest that antiviral treatment is not recommended if patients with HBeAg-positive chronic hepatitis B have normal ALT despite the fact that they do present a risk of developing hepatocellular carcinoma (HCC). The authors of this article present different perspectives to the “Hepatology” editor for this treatment guide and respond accordingly. Now make a report. To the Editor (Geier et al): At present, the global chronic HBV infection reached 350 million, is the main cause of cirrhosis and liver cancer, but also one of the top ten major human causes of death. For chronic HBV infection